Articles with public access mandates - Byron CreeseLearn more
Not available anywhere: 4
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in …
C Ballard, A Thomas, S Gerry, LM Yu, D Aarsland, C Merritt, A Corbett, ...
Journal of the American Medical Directors Association 16 (4), 316-322, 2015
Mandates: National Institute for Health Research, UK
Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease
B Creese, A Corbett, E Jones, C Fox, C Ballard
Journal of the American Medical Directors Association 15 (12), 934-937, 2014
Mandates: National Institute for Health Research, UK
A new tool to identify patients with Parkinson's disease at increased risk of dementia
D Aarsland, B Creese, KR Chaudhuri
The Lancet Neurology 16 (8), 576-578, 2017
Mandates: German Research Foundation, National Institute for Health Research, UK …
Neuropsychiatric symptoms in AD: the search for mechanisms
B Creese, K Lunnon
Nature Reviews Neurology 18 (11), 639-640, 2022
Mandates: US National Institutes of Health
Available somewhere: 67
Cognitive decline in Parkinson disease
D Aarsland, B Creese, M Politis, KR Chaudhuri, DH Ffytche, D Weintraub, ...
Nature Reviews Neurology 13 (4), 217-231, 2017
Mandates: US National Institutes of Health, National Institute for Health Research, UK
The psychosis spectrum in Parkinson disease
DH Ffytche, B Creese, M Politis, KR Chaudhuri, D Weintraub, C Ballard, ...
Nature Reviews Neurology 13 (2), 81-95, 2017
Mandates: US National Institutes of Health, National Institute for Health Research, UK …
Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020
B Creese, Z Khan, W Henley, S O’Dwyer, A Corbett, MV Da Silva, K Mills, ...
International psychogeriatrics 33 (5), 505-514, 2021
Mandates: National Institute for Health Research, UK
Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults
B Creese, H Brooker, Z Ismail, KA Wesnes, A Hampshire, Z Khan, ...
The American Journal of Geriatric Psychiatry 27 (8), 823-834, 2019
Mandates: National Institute for Health Research, UK
Psychosis in Alzheimer disease—mechanisms, genetics and therapeutic opportunities
Z Ismail, B Creese, D Aarsland, HC Kales, CG Lyketsos, RA Sweet, ...
Nature Reviews Neurology 18 (3), 131-144, 2022
Mandates: US National Institutes of Health
Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults
B Creese, A Griffiths, H Brooker, A Corbett, D Aarsland, C Ballard, Z Ismail
International psychogeriatrics 32 (6), 705-717, 2020
Mandates: National Institute for Health Research, UK
Validation of the Cohen-Mansfield agitation inventory observational (CMAI-O) tool
AW Griffiths, CP Albertyn, NL Burnley, B Creese, R Walwyn, I Holloway, ...
International psychogeriatrics 32 (1), 75-85, 2020
Mandates: National Institute for Health Research, UK
Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease
B Creese, Z Ismail
Alzheimer's research & therapy 14, 1-5, 2022
Mandates: Canadian Institutes of Health Research
Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults
B Creese, R Arathimos, H Brooker, D Aarsland, A Corbett, C Lewis, ...
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 13 (1 …, 2021
Mandates: Alzheimers's UK, National Institute for Health Research, UK
Revisiting criteria for psychosis in Alzheimer’s disease and related dementias: toward better phenotypic classification and biomarker research
CE Fischer, Z Ismail, JM Youakim, B Creese, S Kumar, N Nuñez, ...
Journal of Alzheimer's disease 73 (3), 1143-1156, 2020
Mandates: US National Institutes of Health
Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes …
CA Surr, REA Walwyn, A Lilley-Kelly, R Cicero, D Meads, C Ballard, ...
Trials 17, 1-17, 2016
Mandates: National Institute for Health Research, UK
Psychosis in Alzheimer’s disease
C Ballard, HC Kales, C Lyketsos, D Aarsland, B Creese, R Mills, ...
Current neurology and neuroscience reports 20, 1-10, 2020
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer’s disease
B Creese, E Vassos, S Bergh, L Athanasiu, I Johar, A Rongve, ...
Translational psychiatry 9 (1), 273, 2019
Mandates: US Department of Defense, US National Institutes of Health, Canadian …
Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease
MAA DeMichele-Sweet, L Klei, B Creese, JC Harwood, EA Weamer, ...
Molecular psychiatry 26 (10), 5797-5811, 2021
Mandates: US National Institutes of Health, UK Medical Research Council
Vitamin D supplementation and incident dementia: Effects of sex, APOE, and baseline cognitive status
M Ghahremani, EE Smith, HY Chen, B Creese, Z Goodarzi, Z Ismail
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 15 (1 …, 2023
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Dementia Care Mapping™ to reduce agitation in care home residents with dementia: the EPIC cluster RCT.
CA Surr, I Holloway, REA Walwyn, AW Griffiths, D Meads, R Kelley, ...
Health Technology Assessment (Winchester, England) 24 (16), 1, 2020
Mandates: National Institute for Health Research, UK
Publication and funding information is determined automatically by a computer program